Literature DB >> 10791218

Highly aggressive policy of hepatic resections for neuroendocrine liver metastases.

G L Grazi1, M Cescon, F Pierangeli, G Ercolani, A Gardini, A Cavallari, A Mazziotti.   

Abstract

BACKGROUND/AIMS: Neuroendocrine tumors are usually slow growing and carry a prolonged prognosis. The presence of liver metastases significantly impairs long-term survival. The clinical experience with 28 patients admitted since 1981 for liver metastases from neuroendocrine tumors was retrospectively reviewed to analyze the clinical and surgical management and to evaluate their outcome.
METHODOLOGY: Surgery was indicated in 25 (89.2%) patients. Three had metachronous metastases. A correct diagnosis of these liver metastases was achieved before laparotomy in 15 (68.1%) of the remaining 22. The primary tumor site, unknown in 14/22 patients, was located during surgery only in 8 (57.1%).
RESULTS: Due to tumoral spread, surgery was limited to exploration in 3 cases. Liver resections were performed in 19/22 patients (3 for palliation): 11/19 (57.9%) were major hepatectomies and in 8/19 (42.1%) cases they were accomplished by procedures for removing the primary tumor. Overall, curative procedures were carried out in 16/28 (57.1%). Resections were performed in 6 cases without the knowledge of the primary site. There was no operative mortality. Overall recurrence rate was 50.0%. Four-year actuarial survival was 92.6% after resection and 18.5% for patients that did not receive surgery (P < 0.001).
CONCLUSIONS: Our experience confirms that the small number of patients makes the management of liver metastases from neuroendocrine tumors difficult to plan. In consideration of the satisfactory results achieved with an aggressive policy of resection, we advise referral of these patients to specialized liver units where major hepatic procedures, even if extended, can be safely performed.

Entities:  

Mesh:

Year:  2000        PMID: 10791218

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  22 in total

1.  Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours.

Authors:  J K Ramage; A H G Davies; J Ardill; N Bax; M Caplin; A Grossman; R Hawkins; A M McNicol; N Reed; R Sutton; R Thakker; S Aylwin; D Breen; K Britton; K Buchanan; P Corrie; A Gillams; V Lewington; D McCance; K Meeran; A Watkinson
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

2.  Chromogranin A, a marker of the therapeutic success of resection of neuroendocrine liver metastases: preliminary report.

Authors:  Karl Søndenaa; Jon Sen; Frank Heinle; Lars Fjetland; Einar Gudlaugsson; Unni Syversen
Journal:  World J Surg       Date:  2004-09       Impact factor: 3.352

3.  Sustained response to FOLFOX and Bevacizumab in metastatic bronchial carcinoid - A case report and review of the literature.

Authors:  Ikechukwu Akunyili; Monica T Garcia-Buitrago; Jessica Macintyre; Joe Levi; Caio M Rocha Lima
Journal:  J Gastrointest Oncol       Date:  2011-06

Review 4.  When should a liver resection be performed in patients with liver metastases from neuroendocrine tumours? A systematic review with practice recommendations.

Authors:  Mickaël Lesurtel; David M Nagorney; Vincenzo Mazzaferro; Robert T Jensen; Graeme J Poston
Journal:  HPB (Oxford)       Date:  2014-03-17       Impact factor: 3.647

5.  Surgical therapy of neuroendocrine neoplasm with hepatic metastasis: patient selection and prognosis.

Authors:  F M Watzka; C Fottner; M Miederer; A Schad; M M Weber; G Otto; H Lang; T J Musholt
Journal:  Langenbecks Arch Surg       Date:  2015-02-15       Impact factor: 3.445

Review 6.  Role of surgery and transplantation in the treatment of hepatic metastases from neuroendocrine tumor.

Authors:  Sayee Sundar Alagusundaramoorthy; Roberto Gedaly
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

7.  Neuroendocrine hepatic metastases: does aggressive management improve survival?

Authors:  John G Touzios; James M Kiely; Susan C Pitt; William S Rilling; Edward J Quebbeman; Stuart D Wilson; Henry A Pitt
Journal:  Ann Surg       Date:  2005-05       Impact factor: 12.969

Review 8.  Multimodal management of neuroendocrine liver metastases.

Authors:  Andrea Frilling; Georgios C Sotiropoulos; Jun Li; Oskar Kornasiewicz; Ursula Plöckinger
Journal:  HPB (Oxford)       Date:  2010-08       Impact factor: 3.647

9.  Curative versus palliative surgical resection of liver metastases in patients with neuroendocrine tumors: a meta-analysis of observational studies.

Authors:  Stefano Bacchetti; Enrico Maria Pasqual; Serena Bertozzi; Ambrogio P Londero; Andrea Risaliti
Journal:  Gland Surg       Date:  2014-11

10.  The role of liver resections for metastases from lung carcinoma.

Authors:  Giorgio Ercolani; Matteo Ravaioli; Gian Luca Grazi; Matteo Cescon; Giovanni Varotti; Massimo Del Gaudio; Gaetano Vetrone; Matteo Zanello; Alfonso Principe; Antonio Daniele Pinna
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.